Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Baker Bros. Advisors Lp
Form 13F · Q2 2026

Baker Bros. Advisors Lp

CIK 1263508Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$20.0B
Reported book value
84
Positions
12
Quarters on record
Top 50
Positions

Baker Bros. Advisors Lp — holdings

Top 50 positions of 84, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1INCY Incyte Corp30.8M+0.1%$3.5B17.5%
2ONC Beone Medicines Ltd8.8M+0.0%$2.5B12.6%
3RVMD Revolution Medicines Inc11.4M+19.8%$2.1B10.7%
4MDGL Madrigal Pharmaceuticals Inc2.1M+0.1%$1.2B5.8%
5ACAD Acadia Pharmaceuticals Inc42.9M+0.0%$1.1B5.4%
6KYMR Kymera Therapeutics Inc8.7M+0.0%$993M5.0%
7INSM Insmed Inc8.8M+18.5%$938M4.7%
8CELC Celcuity Inc7.9M+0.0%$828M4.2%
9KOD Kodiak Sciences Inc19.9M+0.0%$776M3.9%
10RYTM Rhythm Pharmaceuticals Inc5.6M+0.0%$622M3.1%
11PRAX Praxis Precision Medicines I1.8M+0.0%$587M2.9%
12ALKS Alkermes Plc10.0M+0.0%$525M2.6%
13SMMT Summit Therapeutics Inc32.8M−9.9%$478M2.4%
14GRAL Grail Inc4.0M+0.0%$275M1.4%
15ABCL Abcellera Biologics Inc33.0M+9.0%$259M1.3%
16IMVT Immunovant Inc5.4M−0.4%$209M1.0%
17IDYA Ideaya Biosciences Inc5.0M+26.9%$187M0.9%
18KINIKSA PHARMACEUTICALS INTL Kiniksa Pharmaceuticals Intl2.8M+0.3%$181M0.9%
19ROIV Roivant Sciences Ltd4.7M−3.1%$167M0.8%
20ARWR Arrowhead Pharmaceuticals In2.0M+0.0%$162M0.8%
21IONS Ionis Pharmaceuticals Inc2.0M+0.0%$162M0.8%
22EWTX Edgewise Therapeutics Inc3.7M−43.7%$150M0.8%
23REPL Replimune Group Inc11.0M+0.0%$122M0.6%
24NRIX Nurix Therapeutics Inc4.7M+0.0%$113M0.6%
25STOK Stoke Therapeutics Inc3.3M+0.0%$109M0.5%
26GLUE Monte Rosa Therapeutics Inc4.3M+0.0%$105M0.5%
27IMTX Immatics N.V9.5M−12.9%$96M0.5%
28DNLI Denali Therapeutics Inc3.7M+0.1%$96M0.5%
29CRINETICS PHARMACEUTICALS IN Crinetics Pharmaceuticals In2.4M+0.0%$88M0.4%
30DNTH Dianthus Therapeutics Inc852,164+0.0%$83M0.4%
31GPCR Structure Therapeutics Inc1.4M+0.0%$77M0.4%
32RAPP Rapport Therapeutics Inc1.5M+0.0%$64M0.3%
33ALMS Alumis Inc2.0M+0.0%$57M0.3%
34PRLD Prelude Therapeutics Inc10.1M+0.0%$54M0.3%
35RLAY Relay Therapeutics Inc2.8M+143.7%$53M0.3%
36MIRM Mirum Pharmaceuticals Inc445,975+0.0%$52M0.3%
37BCYC Bicycle Therapeutics Plc10.9M+0.0%$46M0.2%
38ELVN Enliven Therapeutics Inc905,191+0.0%$46M0.2%
39CLDX Celldex Therapeutics Inc New1.2M+77.7%$44M0.2%
40VRDN Viridian Therapeutics Inc2.4M+20.9%$44M0.2%
41DSGN Design Therapeutics Inc2.7M+3.6%$39M0.2%
42TRDA Entrada Therapeutics Inc5.1M+0.0%$37M0.2%
43FTH Faeth Therapeutics Inc1.3M—$32M0.2%
44AKTS Aktis Oncology Inc996,351+0.0%$32M0.2%
45NGNE Neurogene Inc991,691+0.0%$31M0.2%
46JBIO Jade Biosciences Inc1.2M−25.0%$27M0.1%
47TSHA Taysha Gene Therapies Inc4.0M+0.0%$27M0.1%
48RCUS Arcus Biosciences Inc844,816+103.3%$26M0.1%
49IRON Disc Medicine Inc349,657+0.0%$26M0.1%
50ABSI Absci Corporation2.1M+0.0%$25M0.1%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.